You are here: Industry Insights > Breast Cancer

News List

Home State Health Urges Breast Cancer Screenings After Delays Due to COVID-19 Pandemic prnewswire
October 23, 2020
As healthcare facilities across Missouri resume scheduling routine appointments and screenings, Home State Health wants to remind communities of the importance of taking care of their health.
FDA accepts review for ANGLE’s Parsortix system for metastatic breast cancer pharmatimes
October 22, 2020
Liquid biopsy company ANGLE has announced that the US Food and Drug Administration has accepted its submission for substantive review of its Parsortix system for use with metastatic breast cancer (MBC) patients.
Pfizer’s Ibrance flunks early breast cancer trial pharmatimes
October 14, 2020
Pfizer’s oral CDK4/6 inhibitor Ibrance has failed to meet the primary endpoint of improved invasive disease-free survival (iDFS) in early breast cancer, nixing its chances in the adjuvant setting.
IBRANCE (palbociclib) fails trial for early breast cancer treatment expresspharma
October 10, 2020
No unexpected safety signals were observed and it did not meet improved invasive disease-free survival in women with HR+, HER2- early breast cancer in the PENELOPE-B trial.
Menarini Ricerche Announces Dose Escalation Results of MEN1611 for Breast Cancer americanpharmaceuticalreview
September 27, 2020
Menarini Ricerche announced the results of the dose escalation part of its B-PRECISE-01 clinical trial (NCT03767335) which is evaluating MEN1611, a potent and selective phosphatidylinositol 3-kinase (PI3K) inhibitor in development for the treatment of ...
Trodelvy from Immunomedics extends survival in breast cancer patients expresspharma
September 21, 2020
The FDA granted the drug accelerated approval for its use in metastatic triple-negative breast cancer (mTNBC) patients who had previously received at least two prior therapies.
FDA Announces Efficacy, Safety Concerns with Breast Cancer Treatment americanpharmaceuticalreview
September 14, 2020
The U.S. Food and Drug Administration (FDA) is alerting health care professionals, oncology clinical investigators, and patients that a clinical trial studying the use of atezolizumab (Tecentriq) and paclitaxel in patients with previously untreated ...
Treadwell initiates expansion of cohorts in phase 1 study of CFI-402257 pharmaceutical-business-review
September 01, 2020
Treadwell Therapeutics announced the initiation of three expansion cohorts in its ongoing Phase 1 study evaluating CFI-402257, a selective and highly potent oral inhibitor of tyrosine threonine kinase (TTK).
Odonate announces positive top-line results for Tesetaxel in phase 3 metastatic breast cancer trial pharmaceutical-business-review
August 27, 2020
Odonate Therapeutics announced positive top-line results from CONTESSA, a Phase 3 study of tesetaxel in patients with metastatic breast cancer (MBC).
Oncolytics Biotech Doses First Patient in Pelareorep-anti-PD-1 Study for Breast Cancer americanpharmaceuticalreview
August 27, 2020
Oncolytics Biotech® announced the first patient has been dosed in the Company's investigator-sponsored phase 2 study of pelareorep-anti-PD-1 combination therapy in unresectable locally advanced or metastatic triple-negative breast cancer (TNBC).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 26 27 Next page